scholarly journals Chronic atrial fibrillation in patients with paroxysmal atrial fibrillation, atrioventricular node ablation and pacemakers

EP Europace ◽  
1999 ◽  
Vol 1 (1) ◽  
pp. 30-34 ◽  
Author(s):  
J. M. McComb ◽  
G. M. Gribbin

Abstract Aims This study examined the factors associated with the development of chronic (or permanent) atrial fibrillation (AF) in patients who had undergone atrioventricular (AV) node ablation with permanent pacing because of paroxysmal AF. Methods A retrospective review of case notes of all 65 consecutive patients identified as having had paroxysmal atrial arrhythmias, AV node ablation and permanent pacemaker implantation was performed. Atrial rhythm was established from all pacing records and from the surface ECG. Treatment with anti-arrhythmic drugs and with warfarin was recorded. A multivariate analysis was undertaken, using atrial rhythm on final ECG and chronic AF as outcome measures. Results During a mean follow-up of 30 months, 42% of patients with paroxysmal AF had developed chronic AF. Multivariate analysis showed that increasing age, history of electrical cardioversion and VVI pacing all contributed to the development of chronic AF. 25/62 patients were taking warfarin, and four had had strokes (2·5%/year). Conclusions The majority of patients with paroxysmal atrial arrhythmias treated with AV node ablation and pacing develop chronic AF eventually. Stroke remains a risk, particularly in those who develop chronic AF.

Author(s):  
Cheng-ming Ma ◽  
Yong-mei Cha ◽  
yingxue Dong ◽  
Lianjun Gao ◽  
Yunlong Xia

Wenckebach phenomenon is a well-known electrophysiological character of the atrioventricular node (AVN). AVN-pacing during permanent pacemaker implantation is rare. We herein report the first case of Wenckebach phenomenon in a heart failure patient with chronic atrial fibrillation for more than 30 years during the His-bundle pacing (HBP) procedure. The patient’s symptoms improved significantly. AVN-pacing is available, and HBP is helpful for cardiac remodeling and clinical outcomes.


1978 ◽  
Vol 235 (1) ◽  
pp. H1-H17 ◽  
Author(s):  
A. L. Wit ◽  
P. F. Cranefield

Mechanisms that cause reentry were defined in rings of tissue cut from jellyfish as early as 1906 by Mayer. The concepts were developed by Mines and Garrey during the next 10 years. Lewis then tried to demonstrate that reentry caused atrial flutter. Lewis, Garrey, and later Moe also proposed that atrial fibrillation was caused by reentry. Rosenblueth provided additional experimental evidence that reentry could cause atrial arrhythmias after crushing the intercaval bridge of atrial muscle. Recent studies by Allessie using microelectrodes have provided detailed evidence for reentry in atrial tissue. Mines in 1913 also proposed that reentry could occur in the AV node. Scherf then introduced the concept of functional longitudinal dissociation as a cause of return extrasystoles and this was later shown to happen in the node by Moe and his colleagues. Reentry can also occur between atria and ventricles utilizing accessory connecting pathways. Schmitt and Erlanger in 1913 were the first to do experiments which indicated that reentry can also occur in the ventricles. Subsequently it was shown that reentry can occur in Purkinje fiber bundles. Reentry in ventricular muscle may also cause some of the arrhythmias that occur after myocardial infarction.


2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
A Grosse ◽  
R Surber ◽  
K Kirsch ◽  
P C Schulze

Abstract Background Arrhythmias in elderly patients (>70 years) are common in daily clinical practice. Most frequently, they are based on atrial fibrillation or other atrial tachycardia with an indication for oral anticoagulation and specific antiarrhythmic medications. The electrographic (ECG) documentation related to symptoms is essential before therapy initiation. In case of suspected AVNRT based on surface ECG, an electrophysiological study (EP) with ablation as curative strategy should be planned. Methods We analysed all patients >70 years with AVNRT diagnosed by electrophysiologic (EP) studies between May 2018 and December 2020. Results An EP study for suspected AVNRT was performed in 27 patients >70 years. The diagnosis of AVNRT was confirmed in 20 patients (75%). From all EP- studies with the diagnosis of AVNRT (n=93) in this period, 20 patients (22%) were older than 70 years (mean age 77 years with a range of 70–85 years), 12 were women. In most of the patients, the duration of symptoms was short (3 month). Only 4 patients had symptoms of paroxysmal tachycardia longer than 10 years. Except for 2 patients, all patients had at least one ECG- documentation (12- lead- ECG, Holter- ECG, telemetric ECG and/or in the loop recorder). In 12 patients, a 12- lead- ECG- documentation was available, in 5 patients the tachycardia has been registered in the Holter-ECG and in 1 in a loop recorder. In the 12- lead- ECG before ablation in sinus rhythm the PQ interval was with 196 (120- 300) ms in the upper range. In 16/ 20 patients was during the EP- study a sustained AVNRT (CL 410, 314- 538 ms) inducible. In the others, up to 3 typical AV- nodal- echo beats were induced in the EP- study. A slow pathway ablation/ modification was performed in all patients in typical position. In 2 patients, the implantation of a dual- chamber- pacemaker was necessary due to intermittent high- degree AV-nodal-block during the same hospital stay. In both patients, a first degree AV-block with PQ- interval of 250 and 300 ms was pre-existing. Discussion Especially for the elderly patients with new onset of clinical symptoms of arrhythmia, clinical anamnesis including an ECG- documentation is required for planning the therapeutic strategy. A borderline long PQ- interval as sign of an age- dependent fibrosis in the AV- node and, therefore, altered conduction properties in the AV node can be a cause of AVNRT in these older patients. In patients with pre-existing long PQ- interval (>250 ms), the risk of pacemaker implantation after successful ablation is higher. In this group of patients, medical therapeutic options are limited and often associated with the need of pacemaker implantation. FUNDunding Acknowledgement Type of funding sources: None.


2001 ◽  
Vol 24 (3) ◽  
pp. 61 ◽  
Author(s):  
Anne-Maree Kelly ◽  
Debra Kerr ◽  
Ruth Hew

The objective was to determine the proportion of patients presenting to the Emergency Department (ED) in atrialfibrillation (AF) who are at high risk of thromboembolic stroke as defined by the American Heart Association andwho might benefit from anticoagulation therapy.We enrolled all patients identified as having AF between 28th June 1999 and 26th March 2000. Data collectedincluded demographic information, presenting complaint, discharge diagnosis, risk factors for thromboembolic stroke,contraindications to anticoagulation (as defined by the Stroke Prevention in AF Investigators), admission anddischarge medications, and cardiac rhythm on presentation and at discharge.193 patients were identified within the study period. Two patient histories were not available for review. 121 patientshad a prior history of AF. Of these, 65 patients were at high risk for thromboembolic stroke and had no contra-indicationto anticoagulation therapy. 43 (66%) were on Warfarin at presentation but 14 (22%) were on Aspirinand 8 (12%) were on neither.34% of patients with chronic atrial fibrillation presenting to the ED, at high risk of thromboembolic stroke andwithout contra-indication to anticoagulation, were not anticoagulated on presentation. ED attendance provides anopportunity for intervention for the prevention of stroke in this group.


2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Danielle Daly ◽  
Jennifer Searl Como ◽  
Jason H Wasfy

Intro: Anticoagulation is indicated for many patients with atrial fibrillation (AF) for prevention of cardioembolic stroke, although national proportions of eligible patients receiving anticoagulation remain suboptimal. Automated and semi-automated quality improvement techniques including registries and population health coordinators may help identify and increase eligible patients to receive anticoagulation. Methods: We queried our electronic health record to identify patients without anticoagulation but with atrial fibrillation (as identified as either paroxysmal atrial fibrillation, persistent atrial fibrillation, chronic atrial fibrillation, typical atrial flutter, atypical atrial flutter, or unspecified atrial flutter) either on the problem list or as billed administrative claims between September 2016 - September 2019 in MGH outpatient cardiology clinics. All patients were participating in MGH cardiology, with their primary care based either within MGH or outside of MGH. Then, we conducted detailed chart review to calculate thromboembolic risk with respective CHADS-VASC score and confirmed that the patient was not receiving anticoagulation. A typology was developed as charts were reviewed to categorize reasons for lacking anticoagulation. These categories were grouped into broader categories representing a (1) potential quality problem or (2) appropriate lack of anticoagulation. Results: Of 100 patients, 59 were deemed to have a potential quality problem and 41 were deemed to have appropriate lack of anticoagulation. Of the patients with a potential quality problem, 11 have a CHADS VASC score of 1, 18 have a CHADS VASC score of 2, 6 have a CHADS VASC score of 3, 10 have a CHADS VASC score of 4, and 8 have a CHADS of 5, and 6 have a CHADS VASC of 6 or above. Additionally, 3 patients have been lost to follow up, 12 patients had presented with current symptoms of AF within the last year, and 44 patients exhibited acute history of AF symptoms. 41 patients did not present concern for multiple reasons including: CHADS VASC=0, deceased, patients declined medication, followed by outside cardiologist, technology and medication discrepancies, inaccurate administrative data for AF, and prior major bleeding. Conclusions: We found that most un-anticoagulated AF patients identified by administrative claims and EHR problem lists are likely eligible for anticoagulation. Of those, most have a history of paroxysmal AF. As such, registry-based strategies based on queries of past AF may improve rates of anticoagulation in this population. Since automated queries still detect many patients with contraindications such as bleeding or inaccurate administrative data, manual review of administrative queries is likely to be important in quality efforts for AF.


EP Europace ◽  
1999 ◽  
Vol 1 (1) ◽  
pp. 35-39 ◽  
Author(s):  
L. Gianfranchi ◽  
M. Brignole ◽  
C. Menozzi ◽  
G. Lolli ◽  
N. Bottoni

Abstract We evaluated the rate of progression of permanent atrial fibrillation (AF) and identified clinical factors that predict this event in 63 consecutive patients who had undergone AV junctional ablation and DDDR pacemaker implantation for drug-refractory paroxysmal atrial fibrillation/flutter. Immediately after ablation, anti-arrhythmic drugs were discontinued in all cases. Permanent AF was con-sidered to have developed if AF was present on two consecutive 6-monthly examinations with no interim documented sinus rhythm. During a mean follow-up of 23±16 months, 22 (35%) of the 63 patients developed permanent AF. The actuarial estimate of progression of permanent AF was 22%, 40% and 56%, respectively, 1, 2 and 3 years after ablation. Age and underlying heart disease were independent predictors of progression of permanent AF. Only one (6%) of 16 patients with idiopathic AF had permanent AF (low risk group). Among the 47 patients with structural heart disease, permanent AF developed in 18 (62%) of the 29 who were aged >75 years or had >12 arrhythmic episodes per year and a symptom duration >4 years (high risk group), but only in three (17%) of the remaining 18 patients who did not (intermediate risk group). In conclusion, during a 3-year follow-up period, about half of the patients with a history of drug-refractory paroxysmal AF did not develop permanent AF after AV junctional ablation and dual-chamber pacemaker implantation, even in the absence of anti-arrhythmic drug therapy. Moreover, subgroups of patients whose risk of permanent AF progression differed were identified on the basis of simple baseline clinical variables. The results of this study form the necessary background for the correct management of patients after AV junction ablation and for the planning of future trials in this field.


EP Europace ◽  
2008 ◽  
Vol 10 (4) ◽  
pp. 412-418 ◽  
Author(s):  
E. S. Tan ◽  
M. Rienstra ◽  
A. C.P. Wiesfeld ◽  
B. A. Schoonderwoerd ◽  
H. H.F. Hobbel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document